Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News BIOAGE Labs Inc BIOA

Healthcare Drug Manufacturers - Specialty & Generic
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3... see more

Current News (NDAQ:BIOA)

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire 1 day ago

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

GlobeNewswire 5 days ago

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

GlobeNewswire April 21, 2026

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 13, 2026

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

GlobeNewswire March 24, 2026

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

GlobeNewswire February 19, 2026

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

GlobeNewswire January 21, 2026

BioAge Announces Proposed Public Offering

GlobeNewswire January 20, 2026

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

GlobeNewswire January 20, 2026
View More News ››

Opinion & Analysis (NDAQ:BIOA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BIOA)

Be the first to post on this bullboard.

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc.

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ...
View More »

Podcasts